Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 55

1.

Renal function in heart transplant patients after switch to combined mammalian target of rapamycin inhibitor and calcineurin inhibitor therapy.

Helmschrott M, Rivinius R, Bruckner T, Katus HA, Doesch AO.

Drug Des Devel Ther. 2017 Jun 7;11:1673-1680. doi: 10.2147/DDDT.S135503. eCollection 2017.

2.

Judicious Toggling of mTOR Activity to Combat Insulin Resistance and Cancer: Current Evidence and Perspectives.

Ong PS, Wang LZ, Dai X, Tseng SH, Loo SJ, Sethi G.

Front Pharmacol. 2016 Oct 25;7:395. eCollection 2016. Review.

3.

Immunosuppression for in vivo research: state-of-the-art protocols and experimental approaches.

Diehl R, Ferrara F, Müller C, Dreyer AY, McLeod DD, Fricke S, Boltze J.

Cell Mol Immunol. 2017 Feb;14(2):146-179. doi: 10.1038/cmi.2016.39. Epub 2016 Oct 10. Review.

4.

mTOR inhibitors in cancer therapy.

Xie J, Wang X, Proud CG.

F1000Res. 2016 Aug 25;5. pii: F1000 Faculty Rev-2078. doi: 10.12688/f1000research.9207.1. eCollection 2016. Review.

5.

Use of Everolimus in Liver Transplantation: Recommendations From a Working Group.

De Simone P, Fagiuoli S, Cescon M, De Carlis L, Tisone G, Volpes R, Cillo U; Consensus Panel.

Transplantation. 2017 Feb;101(2):239-251. doi: 10.1097/TP.0000000000001438. Review.

6.

New perspectives on the use of mTOR inhibitors in allogeneic haematopoietic stem cell transplantation and graft-versus-host disease.

Lutz M, Mielke S.

Br J Clin Pharmacol. 2016 Nov;82(5):1171-1179. doi: 10.1111/bcp.13022. Epub 2016 Jun 22. Review.

7.

Influence of mTOR-inhibitors and mycophenolic acid on human cholangiocellular carcinoma and cancer associated fibroblasts.

Heits N, Heinze T, Bernsmeier A, Kerber J, Hauser C, Becker T, Kalthoff H, Egberts JH, Braun F.

BMC Cancer. 2016 May 20;16:322. doi: 10.1186/s12885-016-2360-8.

8.

Immunosuppressive potency of mechanistic target of rapamycin inhibitors in solid-organ transplantation.

Baroja-Mazo A, Revilla-Nuin B, Ramírez P, Pons JA.

World J Transplant. 2016 Mar 24;6(1):183-92. doi: 10.5500/wjt.v6.i1.183. Review.

9.

Potential therapeutic effects of the MTOR inhibitors for preventing ageing and progeria-related disorders.

Evangelisti C, Cenni V, Lattanzi G.

Br J Clin Pharmacol. 2016 Nov;82(5):1229-1244. doi: 10.1111/bcp.12928. Epub 2016 May 18. Review.

10.

Twelve-month efficacy and safety of the conversion to everolimus in maintenance heart transplant recipients.

Manito N, Delgado JF, Crespo-Leiro MG, Arizón JM, Segovia J, González-Vílchez F, Mirabet S, Lage E, Pascual-Figal D, Díaz B, Palomo J, Rábago G, Sanz M, Blasco T, Roig E.

World J Transplant. 2015 Dec 24;5(4):310-9. doi: 10.5500/wjt.v5.i4.310.

11.

The Influence of Immunosuppressive Agents on the Risk of De Novo Donor-Specific HLA Antibody Production in Solid Organ Transplant Recipients.

OʼLeary JG, Samaniego M, Barrio MC, Potena L, Zeevi A, Djamali A, Cozzi E.

Transplantation. 2016 Jan;100(1):39-53. doi: 10.1097/TP.0000000000000869. Review.

12.

Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex.

MacKeigan JP, Krueger DA.

Neuro Oncol. 2015 Dec;17(12):1550-9. doi: 10.1093/neuonc/nov152. Epub 2015 Aug 19. Review.

13.

Everolimus-eluting stent platforms in percutaneous coronary intervention: comparative effectiveness and outcomes.

Panoulas VF, Mastoris I, Konstantinou K, Tespili M, Ielasi A.

Med Devices (Auckl). 2015 Jul 24;8:317-29. doi: 10.2147/MDER.S66360. eCollection 2015. Review.

14.

Healing arterial ulcers: Endothelial lining regeneration upon vascular denudation injury.

McDonald AI, Iruela-Arispe ML.

Vascul Pharmacol. 2015 Sep;72:9-15. doi: 10.1016/j.vph.2015.06.007. Epub 2015 Jun 18. Review.

15.

Oscillatory mTOR inhibition and Treg increase in kidney transplantation.

Sabbatini M, Ruggiero G, Palatucci AT, Rubino V, Federico S, Giovazzino A, Apicella L, Santopaolo M, Matarese G, Galgani M, Terrazzano G.

Clin Exp Immunol. 2015 Nov;182(2):230-40. doi: 10.1111/cei.12669. Epub 2015 Aug 28.

16.

mTOR kinase: a possible pharmacological target in the management of chronic pain.

Lisi L, Aceto P, Navarra P, Dello Russo C.

Biomed Res Int. 2015;2015:394257. doi: 10.1155/2015/394257. Epub 2015 Jan 1. Review.

17.

Efficacy of dual PI-3K and mTOR inhibitors in vitro and in vivo in acute lymphoblastic leukemia.

Wong J, Welschinger R, Hewson J, Bradstock KF, Bendall LJ.

Oncotarget. 2014 Nov 15;5(21):10460-72.

18.

The role of everolimus in liver transplantation.

Ganschow R, Pollok JM, Jankofsky M, Junge G.

Clin Exp Gastroenterol. 2014 Sep 2;7:329-43. doi: 10.2147/CEG.S41780. eCollection 2014. Review.

19.

Multiple indications for everolimus after liver transplantation in current clinical practice.

Bilbao I, Dopazo C, Lazaro J, Castells L, Caralt M, Sapisochin G, Charco R.

World J Transplant. 2014 Jun 24;4(2):122-32. doi: 10.5500/wjt.v4.i2.122.

20.

Everolimus-eluting stents improve vascular response in a diabetic animal model.

Habib A, Karmali V, John MC, Polavarapu R, Nakazawa G, Pachura K, Davis T, Kolodgie FD, Virmani R, Finn AV.

Circ Cardiovasc Interv. 2014 Aug;7(4):526-32. doi: 10.1161/CIRCINTERVENTIONS.113.001023. Epub 2014 Jun 10.

Supplemental Content

Support Center